Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female 18 years of age or older~* Patient is HIV positive~* Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART~Extension Study:~* The planned extension study did not take place as the study was terminated after the Week 48 analysis.~Exclusion Criteria:~* Patient is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence~* Patient has documented resistance to tenofovir or emtricitabine~* Patient is currently participating or has participated in a study with an investigational compound or device within 45 days of signing informed consent~* Patient is pregnant or breastfeeding, or expecting to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir 400 mg b.i.d. (Type: ACTIVE_COMPARATOR): None
- Raltegravir 800 mg q.d. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).